CORRIGENDUM


Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results



Adel El Sayed1, *, Abd El-Monim Hilal2, Ahmed Abogamal3, Alaa Labeeb4, Amin Abdel Hamid3, Amira El Gerby2, Ayman Farouk Darwish5, Aziza Sayed Omar6, Dahlia Abdel Mohsen7, Dalia Faiez1, A M Abda8, Fatemah A. Elshabacy9, Manal Tayel10, Mohamed Elwakd11, Mohamed Mortada12, Mohsen H.Elshahaly6, Nevine Mohannad10, Raga A. Kader2, S. Z. Hassan11, Samah A. Elbakry7, Sherif Refaat13
1 Department of Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
3 Rheumatology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
4 Rheumatology, Physical Medicine and Rehabilitation Department, Menoufia University, Al Minufiyah, Egypt
5 Rheumatology & Rehabilitation Department, Minia University, Minia, Egypt
6 Rheumatology, Physical Medicine &Rehabilitation Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
7 Rheumatology & Internal Medicine Department, Ain Shams University, Cairo, Egypt
8 Department of Rheumatology and Rehabilitation, Assiut University, Assiut, Egypt
9 Rheumatology Department, Benha Teaching Hospital, Benha, Egypt
10 Rheumatology & Internal Medicine Department, Alexandria University, Alexandria, Egypt
11 Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
12 Rheumatology and Rehabilitation Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
13 Rheumatology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 146
Abstract HTML Views: 153
PDF Downloads: 77
ePub Downloads: 92
Total Views/Downloads: 468
Unique Statistics:

Full-Text HTML Views: 112
Abstract HTML Views: 110
PDF Downloads: 66
ePub Downloads: 75
Total Views/Downloads: 363



© 2019 El Sayed et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Rheumatology, Faculty of Medicine, Ain Shams University, Ramsis St., Abbasseya, Cairo, Egypt; Tel: +00201005265425; E-mail: adel.elsayed1303@gmail.com




Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results

The Open Rheumatology Journal, 2018, 12: 323-331

The last paragraph on page 327 is revised as follows:

In regards to patients receiving leflunomide as a first-line therapy, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 35.40 ±16.49 at baseline visit to reach 15.04 ±9.63 after 6 weeks from treatment initiation. After additional 6 weeks, further significant decrease (p=0.028) was observed in the mean ±SD CDAI total score to reach 11.83 ±5.88.

The original paragraph provided is mentioned below:

In regards to patients receiving leflunomide as a first-line therapy, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 35.40 ±16.49 at baseline visit to reach 15.04 ±9.63 after 6 weeks from treatment initiation, however after additional 6 weeks, the mean ±SD CDAI total score was insignificantly decreased (p=0.028) to be 11.83 ± 5.88.

The first paragraph on page 328 is revised as follows:

In a similar pattern, in patients receiving leflunomide as add-on therapy to other DMARDs with or without steroids, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 37.09 ±14.12 at baseline visit to reach 20.42 ±9.36 after 6 weeks from treatment initiation, and it was significantly further decreased (p<0.001) to reach 15.98 ±10.32 after additional 6 weeks.

The original paragraph provided is mentioned below:

In patients receiving leflunomide as add-on therapy to other DMARDs with or without steroids, the mean ±SD CDAI total score was significantly decreased from 37.09 ±14.12 at baseline visit to reach 20.42 ±9.36 after 6 weeks from treatment initiation. Unlike patients receiving leflunomide as a first line therapy, in this group, the mean ±SD CDAI total score was significantly further decreased to reach 15.98 ±10.32 after an additional 6 weeks.